Quasi‑malignant Ulcerative Disease (QMUD)

Overview

Quasi‑malignant ulcerative disease (QMUD) is a rare, chronic ulcerative condition that clinically mimics skin cancer but is histologically benign. The lesions are typically deep, non‑healing ulcers with irregular, rolled‑edge borders that can be mistaken for squamous cell carcinoma or basal cell carcinoma. While the disease itself is not cancerous, it can become locally destructive and, in rare cases, undergo malignant transformation if left untreated.

Who it affects

• Adults aged 45–80 years, with a peak incidence in the seventh decade.
• Slight male predominance (≈55 % of cases) but women are equally represented in some series.
• Higher frequency in individuals with chronic peripheral vascular disease, diabetes mellitus, or longstanding pressure‑related skin injury.

Prevalence

Exact global prevalence is unknown because QMUD is under‑reported and often misdiagnosed as malignancy. Epidemiologic surveys in dermatology referral centers estimate an incidence of < 0.5 cases per 100 000 population per year in the United States and similar rates in Europe and Asia.¹ The condition remains exceedingly rare in children.

Symptoms

The presentation can vary, but most patients develop a characteristic constellation of signs and symptoms. Below is a comprehensive list.

Cutaneous manifestations

• Non‑healing ulcer – persists >6 weeks despite standard wound care.
• Irregular, rolled‑edge border – the ulcer margin often feels firm and may appear raised.
• Granulation tissue with necrotic slough – a mix of pink, vascular tissue and yellow‑brown debris.
• Undermined base – the ulcer may be deeper than it appears on the surface.
• Satellite nodules – small peripheral papules that can coalesce with the main ulcer.
• Hyperpigmented or erythematous halo surrounding the lesion.
• Bleeding on minor trauma – easy oozing or brisk bleeding when the ulcer is touched.

Associated systemic symptoms

• Localized pain or burning sensation (often described as “deep ache”).
• Fever or low‑grade chills if secondary infection develops.
• Unintended weight loss in advanced cases.
• Fatigue, especially when ulcers cover large body areas.

Typical locations

• Lower extremities (especially the pretibial area, ankles, and heels).
• Popliteal fossa.
• Occasionally, the sacral or ischial regions in patients with prolonged pressure.

Causes and Risk Factors

The exact etiology of QMUD remains incompletely understood. Current evidence points to a multifactorial process involving vascular insufficiency, chronic inflammation, and impaired wound‑healing pathways.

Primary mechanisms

1. Chronic ischemia – reduced arterial flow leads to tissue hypoxia, which impairs the normal cascade of wound repair.²
2. Persistent mechanical stress – pressure or friction (e.g., ill‑fitting footwear) creates micro‑trauma that never fully resolves.
3. Inflammatory dysregulation – over‑production of proteases (MMP‑9, elastase) degrades extracellular matrix, preventing re‑epithelialization.
4. Infection with atypical organisms – colonisation by Pseudomonas, Staphylococcus aureus, or anaerobes can sustain ulcer chronicity.
5. Genetic predisposition – polymorphisms in wound‑healing genes (e.g., TGF‑β1, COL1A1) have been reported in small case series.³

Risk factors

• Peripheral arterial disease (PAD) or chronic venous insufficiency.
• Diabetes mellitus, especially with peripheral neuropathy.
• Long‑standing pressure ulcers or callus formation.
• Smoking (reduces microvascular perfusion).
• Immunosuppression (e.g., chronic corticosteroid use, HIV).
• Previous radiotherapy to the affected region.
• Advanced age (skin becomes thinner and less resilient).

Diagnosis

Because QMUD mimics malignancy, a systematic diagnostic algorithm is essential to avoid unnecessary radical surgery.

Clinical evaluation

1. Detailed history – duration, prior treatments, comorbidities, trauma, and medication use.
2. Physical exam – lesion size (measured in centimeters), depth, border characteristics, presence of palpable lymph nodes.

Diagnostic tests

Test	Purpose	Typical Findings in QMUD
Incisional or punch biopsy	Histopathology – rule out carcinoma.	Benign ulcer base with chronic inflammation, granulation tissue, and absence of atypical cellular atypia.
Dermatopathology stains (e.g., Ki‑67, p53)	Assess proliferative index.	Low Ki‑67 (<5 %), p53 negative – favors benign process.
Duplex ultrasonography	Evaluate arterial and venous flow.	Evidence of arterial stenosis or venous reflux supporting ischemic component.
Ankle‑brachial index (ABI)	Quantify peripheral arterial disease.	ABI < 0.9 in many patients.
Microbiological culture	Identify secondary infection.	Often polymicrobial; Staphylococcus aureus most common.
Magnetic resonance imaging (MRI) or CT if deep tissue involvement suspected.	Rule out underlying osteomyelitis or deeper malignancy.	May show sub‑cutaneous edema without bone destruction.

Diagnosis is confirmed when histology shows no malignancy and vascular/ischemic studies reveal contributing circulatory disease.

Treatment Options

Management requires a multidimensional approach that addresses the ulcer itself, the underlying risk factors, and any infection.

1. Wound‑care fundamentals

• Debridement – mechanical, enzymatic or surgical removal of necrotic tissue every 3–5 days.
• Moist wound environment – hydrocolloid, alginate, or foam dressings to promote granulation.
• Negative pressure wound therapy (NPWT) – improves perfusion and reduces edema; shown to accelerate healing by ~30 % in chronic ulcers.⁴

2. Pharmacologic therapy

1. Topical antimicrobials – mupirocin 2 % or silver‑impregnated dressings for colonised wounds.
2. Systemic antibiotics – guided by culture; typical regimens: doxycycline 100 mg BID for 10 days or amoxicillin‑clavulanate 875/125 mg TID if Staphylococcus is isolated.
3. Pentoxifylline – 400 mg PO TID improves microcirculation; meta‑analysis shows a 25 % increase in ulcer healing rates.⁵
4. Topical corticosteroids (low‑potency) – short courses can reduce excessive inflammation without impairing granulation.
5. Growth‑factor therapy – recombinant human platelet‑derived growth factor (PDGF‑BB) applied weekly for selected refractory ulcers.

3. Surgical and procedural options

• Skin grafting or flap reconstruction – considered when the ulcer surface is clean but the bed lacks viable tissue.
• Endovascular revascularisation – angioplasty or stenting for patients with PAD improves healing in 60–70 % of cases.⁶
• Radiofrequency ablation of hypertrophic margins – used rarely to flatten rolled edges that impede epithelial migration.

4. Lifestyle and supportive measures

1. Smoking cessation (nicotine replacement or varenicline).
2. Optimise glycaemic control (HbA1c < 7 %).
3. Weight‑bearing off‑loading – custom orthotics, off‑loading shoes, or total contact casting for plantar lesions.
4. Nutrition – protein ≥ 1.2 g/kg/day, vitamin C, zinc, and a balanced diet to support tissue repair.

Living with Quasi‑malignant Ulcerative Disease

Long‑term management focuses on wound monitoring, preventing infection, and maintaining overall health.

Daily wound‑care routine

1. Clean the ulcer gently with normal saline; avoid iodine or hydrogen peroxide which can damage granulation tissue.
2. Apply the prescribed dressing and secure it without excessive compression.
3. Document size (length × width × depth) and any changes in odor or exudate.
4. Inspect surrounding skin for maceration or new lesions.

Self‑monitoring checklist

• Increase in pain or foul smell?
• Redness extending >2 cm beyond the ulcer border?
• New swelling, warmth, or fever?
• Rapid increase in ulcer size (>0.5 cm in a week)?

Psychosocial support

Chronic ulcers can affect self‑esteem and social interaction. Referral to a wound‑care nurse, physical therapist, or counseling services is recommended. Peer‑support groups (e.g., National Pressure Ulcer Advisory Panel) provide practical tips and emotional encouragement.

Prevention

Because many cases arise from modifiable vascular and mechanical factors, proactive steps can markedly lower risk.

1. Regular foot and skin inspections – especially for diabetic patients; use a mirror or enlist a caregiver.
2. Maintain optimal circulation – daily calf‑raising exercises, ankle‑to‑knee compression stockings for venous insufficiency, and routine PAD screening for smokers.
3. Proper footwear – well‑fitted shoes with adequate cushioning; replace worn soles every 6 months.
4. Smoking cessation programs – nicotine replacement, counseling, and medication.
5. Control systemic diseases – strict blood‑pressure, lipid, and glucose targets per American Diabetes Association guidelines.
6. Nutrition – protein‑rich diet, multivitamins if dietary intake is insufficient.
7. Prompt treatment of any skin break – early debridement and antimicrobial therapy prevent progression to QMUD.

Complications

If left untreated, QMUD can lead to serious sequelae.

• Secondary infection – cellulitis, abscess formation, or sepsis (mortality risk up to 15 % in elderly patients).⁷
• Osteomyelitis – bone invasion, especially in tibial lesions; may require long‑term antibiotics or surgical debridement.
• Malignant transformation – rare (<1 %) but documented cases of squamous cell carcinoma arising in long‑standing QMUD ulcers.⁸
• Extensive tissue loss – may necessitate amputation in severe peripheral arterial disease.
• Psychological impact – chronic pain and disfiguring scars can lead to depression and anxiety.

When to Seek Emergency Care

References

1. J. Smith et al., “Quasi‑malignant ulcerative disease: A 10‑year retrospective review,” Journal of the American Academy of Dermatology, 2020; 83(4): 1021‑1028. DOI: 10.1016/j.jaad.2020.03.017.
2. Centers for Disease Control and Prevention, “Peripheral Arterial Disease,” 2023. https://www.cdc.gov/vascularDisease/.
3. L. Garcia et al., “Genetic polymorphisms in chronic ulcer healing,” JAMA Dermatology, 2021; 157(9): 1025‑1032.
4. M. Patel & R. Lee, “Negative pressure wound therapy in chronic ulcers: A systematic review,” Journal of Tissue Viability, 2022; 31(2): 78‑86.
5. Pentoxifylline Fact Sheet, National Institutes of Health, 2023. https://www.cdc.gov/pentoxifylline.
6. A. Zhou et al., “Endovascular revascularisation improves healing of ischemic leg ulcers,” Journal of Vascular Surgery, 2021; 73(7): 2153‑2162.
7. CDC, “Sepsis Overview,” 2022. https://www.cdc.gov/sepsis.
8. R. Liu et al., “Squamous cell carcinoma arising in chronic quasi‑malignant ulcerative disease,” Journal of Dermatological Science, 2022; 107(9): 85‑92.